A new bioreactor platform that aims to support the cell and gene therapy (CGT) sector from process development to commercial manufacturing has been launched.
The Quantum Flex Cell Expansion System has been created by medical technology company Terumo Blood and Cell Technologies (Terumo BCT).
Using the system, developers can complete early process development on the same platform as manufacturing. It is hoped that this will lead to reduced cost and risk of unanticipated process deviations in later phases of clinical trials.
“Collaboration is important in meeting the needs of this fast-moving sector. We worked closely with four customers in our early adopter program to pilot the new Quantum Flex platform,” said Delara Motlagh, General Manager, Cell Therapy Technologies.
“The cell culture environment matters so cells can not only grow but thrive. We developed Quantum Flex to provide a scalable, GMP-compliant platform that streamlines cell manufacturing and data management.”
